Terms: = Ovarian cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
124 results:
1. Therapeutic Options Targeting the ataxia-Telangiectasia Mutated (atm)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in ovarian cancer.
Tseng CC; Ku MH; Wu YC; Huang WL; Wu WM; Pai CH; Chen CW
Anticancer Res; 2024 Apr; 44(4):1353-1364. PubMed ID: 38538001
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract] [Full Text] [Related]
3. PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/ovarian cancer.
Ghosh M; Kang MS; Katuwal NB; Hong SD; Jeong YG; Park SM; Kim SG; Moon YW
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069409
[TBL] [Abstract] [Full Text] [Related]
4. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.
Carter J; Hulse M; Sivakumar M; Burtell J; Thodima V; Wang M; Agarwal A; Vykuntam K; Spruance J; Bhagwat N; Rager J; Ruggeri B; Scherle P; Ito K
Cancer Res Commun; 2023 Nov; 3(11):2233-2243. PubMed ID: 37861290
[TBL] [Abstract] [Full Text] [Related]
5. Hepatitis B virus infection disrupts homologous recombination in hepatocellular carcinoma by stabilizing resection inhibitor ADRM1.
Zeng M; Tang Z; Ren L; Wang H; Wang X; Zhu W; Mao X; Li Z; Mo X; Chen J; Han J; Kong D; Ji J; Carr AM; Liu C
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37815873
[TBL] [Abstract] [Full Text] [Related]
6. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract] [Full Text] [Related]
7. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
[TBL] [Abstract] [Full Text] [Related]
8. A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
Horvat N; Causa Andrieu P; Meier A; Ji X; Lakhman Y; Soslow R; Allison D; Gangai N; Rodriguez L; Kattan MW; Chi DS; Hricak H
Gynecol Oncol; 2023 Sep; 176():90-97. PubMed ID: 37478617
[TBL] [Abstract] [Full Text] [Related]
9. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
10. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA; Fontana E; Lee EK; Spigel DR; Højgaard M; Lheureux S; Mettu NB; Carneiro BA; Carter L; Plummer R; Cote GM; Meric-Bernstam F; O'Connell J; Schonhoft JD; Wainszelbaum M; Fretland AJ; Manley P; Xu Y; Ulanet D; Rimkunas V; Zinda M; Koehler M; Silverman IM; Reis-Filho JS; Rosen E
Nat Med; 2023 Jun; 29(6):1400-1411. PubMed ID: 37277454
[TBL] [Abstract] [Full Text] [Related]
11. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
12. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract] [Full Text] [Related]
13. Prevalence of Pathogenic Germline Mutations in 13 Hereditary cancer-Related Genes in Breast cancer Patients in Narathiwat Province, Thailand.
Sukpan P; Kanokwiroon K; Sriplung H; Laochareonsuk W; Choochuen P; Auseng N; Wanawanakorn K; Sangkhathat S
Asian Pac J Cancer Prev; 2023 Feb; 24(2):525-530. PubMed ID: 36853301
[TBL] [Abstract] [Full Text] [Related]
14. The impact of coding germline variants on contralateral breast cancer risk and survival.
Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
[TBL] [Abstract] [Full Text] [Related]
15. Germline cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
Liu Y; Gusev A; Kraft P
Cancer Res; 2023 Apr; 83(8):1191-1202. PubMed ID: 36745477
[TBL] [Abstract] [Full Text] [Related]
16. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract] [Full Text] [Related]
17. Somatic gene mutations in malignant steroid cell tumours and response to multiple treatments.
Nakanishi K; Fukagawa T; Yamada T; Suzuki S
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593625
[TBL] [Abstract] [Full Text] [Related]
18. Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.
Dong L; Wang T; Li N; Yao H; Ying J; Wu L; Yuan G
Cells; 2022 Nov; 11(22):. PubMed ID: 36428992
[TBL] [Abstract] [Full Text] [Related]
19. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract] [Full Text] [Related]
20. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
[Next]
